natgillin/translations-raw huggingface dataset:
Organic anion transporting polypeptides (OATPs) and multidrug resistance-associated protein 2 (MRP2) are involved in MPA's disposition; OATP isoforms, MRP2 and breast cancer resistance protein (BCRP) are transporters associated with the glucuronides' biliary excretion.
Na razporeditev mikofenolne kisline vplivajo organski anionski prenašalni polipeptidi (OATP - Organic anion-transporting polypeptides) in protein za multiplo odpornost na zdravila 2 (MRP2 - Multidrug resistance-associated protein 2).
Cases of BK virus associated nephropathy, as well as cases of JC virus associated progressive multifocal leucoencephalopathy (PML), have been reported in patients treated with immunosuppressants, including Mycophenolate mofetil Teva.
Pri bolnikih, zdravljenih z imunosupresivi, vključno z zdravilom Mofetilmikofenolat Teva, so poročali o primerih nefropatije, povezane z virusom BK, kot tudi progresivne multifokalne levkoencefalopatije (PML), povezane z virusom JC.
Mycophenolate mofetil Teva, the contraceptive requirements for both male and female patients and what to do in case of pregnancy during treatment with Mycophenolate mofetil Teva.
zahteve po kontracepciji za bolnike in bolnice ter da bi vedeli, kaj storiti v primeru zanositve med zdravljenjem z zdravilom Mofetilmikofenolat Teva.
Do not take Mycophenolate mofetil Teva,
Ne jemljite zdravila Mofetilmikofenolat Teva:
A study of the co-administration of mycophenolate mofetil (1°g BID) and combined oral contraceptives containing ethinylestradiol (0.02°mg to 0.04°mg) and levonorgestrel (0.05°mg to 0.15°mg), desogestrel (0.15°mg) or gestodene (0.05°mg to 0.10°mg) conducted in 18 non-transplant women (not taking other immunosuppressants) over 3 consecutive menstrual cycles showed no clinically relevant influence of mycophenolate mofetil on the ovulation suppressing action of the oral contraceptives.
Bolnice, ki jemljejo peroralne kontraceptive V študiji je 18 žensk brez presadka (drugih imunosupresivov niso jemale) sočasno prejemalo 1 g mofetilmikofenolata dvakrat na dan in kombinirane kontraceptive, ki so vsebovali etinilestradiol (0,02 mg do 0,04 mg) in levonorgestrel (0,05 mg do 0,15 mg), desogestrel (0,15 mg) ali gestoden (0,05 mg do 0,10 mg).
PC:
Pokrovček:
Elderly patients receiving Mycophenolate mofetil Teva as part of a combination immunosuppressive regimen, may be at increased risk of certain infections (including cytomegalovirus tissue invasive disease) and possibly gastrointestinal haemorrhage and pulmonary oedema, compared to younger individuals.
Pri starejših bolnikih, ki prejemajo zdravilo Mofetilmikofenolat Teva kot del kombinacije imunosupresivnega režima, je v primerjavi z mlajšimi tveganje za pojav določenih okužb (vključno s citomegalovirusno tkivno invazivno boleznijo), krvavitev v prebavilih in pljučnega edema lahko večje.
CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
D. POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA • Načrt za obvladovanje tveganj (RMP)
AcMPAG is pharmacologically active and is suspected to be responsible for some of MMF´s side effects (diarrhoea, leucopenia).
Ta je farmakološko aktiven in verjetno odgovoren za nekaj neželenih učinkov mofetilmikofenolata
How to take Mycophenolate mofetil Teva
Kako jemati zdravilo Mofetilmikofenolat Teva
Spontaneous abortion (rate of 45% to 49%) and congenital malformations (estimated rate of 23% to 27%) have been reported following MMF exposure during pregnancy.
Po izpostavljenosti mofetilmikofenolatu med nosečnostjo so poročali o spontanem splavu (ocenjeni delež 45 % do 49 %) in kongenitalnih malformacijah (ocenjeni delež
Intravenous mycophenolate mofetil should be administered for the first 4°days following hepatic transplant, with oral Mycophenolate mofetil Teva initiated as soon after this as it can be tolerated.
Odrasli Prve 4 dni po presaditvi jeter je treba dajati mofetilmikofenolat intravensko, takoj ko je bolnik sposoben požirati,
In contrast, there was an increase of approximately 20% in tacrolimus AUC when multiple doses of mycophenolate mofetil (1.5 g taken twice a day [BID], morning and evening) were administered to hepatic transplant patients taking tacrolimus.
Nasprotno, po dajanju večkratnih odmerkov mofetilmikofenolata (1,5 g dvakrat na dan, zjutraj in zvečer) bolnikom z jetrnim presadkom, ki so jemali takrolimus, se je AUC takrolimusa povečala za približno
In a female fertility and reproduction study conducted in rats, oral doses of 4.5 mg/kg/day caused malformations (including anophthalmia, agnathia and hydrocephaly) in the first generation offspring in the absence of maternal toxicity.
V študijah fertilnosti in reproduktivnosti so peroralni odmerki po 4,5 mg/kg/dan pri podganjih samicah povzročili malformacije
Do not take Mycophenolate mofetil Teva if you are breast-feeding.
Dojenje Ne jemljite zdravila Mofetilmikofenolat Teva, če dojite.
Mycophenolate mofetil Teva film-coated tablets should be handled with care.
Zdravilo Mofetilmikofenolat Teva tablete je treba uporabljati previdno Tablet ne drobite.
• Are you taking any medicines containing: o azathioprine or other immunosuppressive agents (which are sometimes given to patients after a transplant operation), o cholestyramine (used to treat patients with high blood cholesterol), o rifampicin (antibiotic), o antacids or proton pump inhibitors (used for acid problem in your stomach such as indigestion), o phosphate binders (used in patients with chronic kidney failure to reduce the absorption of phosphate), o antibiotics (used to treat bacterial infections), o isavuconazole (used to treat fungal infections), o telmisartan (used to treat high blood pressure) o or any other medicines (including those you can buy without a prescription) that your doctor does not know about?
o antacide ali zaviralce protonske črpalke (uporabljajo se pri težavah s kislino v želodcu, kot je dispepsija), o fosfatne vezalce (uporabljajo jih za zmanjšanje absorpcije fosfatov pri bolnikih s kronično ledvično odpovedjo), o antibiotike (uporabljajo se za zdravljenje bakterijskih okužb),
Therefore you should limit your exposure to sunlight and ultraviolet (UV) light by wearing appropriate protective clothing and using a sunscreen with a high protection factor.
Ker zdravilo Mofetilmikofenolat Teva zmanjša obrambno sposobnost vašega organizma, obstaja zvečana možnost nastanka kožnega raka, zato se je treba izogibati sončni svetlobi in ultravijoličnim (UV) žarkom z uporabo zaščitnih oblačil in sončne kreme z visokim zaščitnim faktorjem.
The type and frequency of adverse reactions in a clinical study, which recruited 92 paediatric patients aged 2 to 18°years who were given 600°mg/m2 mycophenolate mofetil orally twice daily, were generally similar to those observed in adult patients given 1°g mycophenolate mofetil twice daily.
18 let, ki so prejemali 600 mg/m2 mofetilmikofenolata peroralno dvakrat na dan, sta bila podobna neželenim učinkom, opaženim pri odraslih bolnikih, ki so prejemali 1 g mofetilmikofenolata dvakrat na dan. Naslednji neželeni učinki povezani z zdravljenjem pa so bili v primerjavi z odraslimi pogostejši pri pediatrični populaciji,
If you are a woman who could become pregnant you must use an effective method of contraception with Mycophenolate mofetil Teva.
Če ste bolnica, ki bi lahko zanosila, morate med zdravljenjem z zdravilom Mofetilmikofenolat Teva uporabljati učinkovito metodo kontracepcije: - preden začnete jemati zdravilo Mofetilmikofenolat Teva; - ves čas zdravljenja z zdravilom Mofetilmikofenolat Teva;
The most common opportunistic infections in patients receiving mycophenolate mofetil (2°g or 3°g daily) with other immunosuppressants in controlled clinical trials in renal (2°g data), cardiac and hepatic transplant patients followed for at least 1°year were candida mucocutaneous, cytomegalovirus (CMV) viraemia/syndrome and Herpes simplex.
(2 g ali 3 g na dan) z drugimi imunosupresivi vsaj eno leto, so bile okužbe z glivicami (Candida mucocutaneus), sindrom CMV/viremija in okužbe z virusom herpesa simpleksa.
The active substance in this medicine is called mycophenolate mofetil. Mycophenolate mofetil Teva is used to prevent your body rejecting a transplanted kidney, heart or liver.
Z zdravilom Mofetilmikofenolat Teva vašemu telesu preprečimo zavrnitev ledvičnega, srčnega ali jetrnega presadka.
Dose adjustment of Mycophenolate mofetil Teva does not appear to be necessary.
Mofetilmikofenolat Teva ni potrebna.
In a single dose study (6 subjects/group), mean plasma MPA AUC observed in subjects with severe chronic renal impairment (glomerular filtration rate < 25 mL/min/1.73 m2) were 28-75% higher relative to the means observed in normal healthy subjects or subjects with lesser degrees of renal impairment.
(glomerulna filtracija < 25 ml/mim/1,73 m2) srednji AUC mikofenolne kisline v plazmi za 28 do 75 % večji kot pri bolnikih z blažjimi stopnjami ledvične okvare ali pri zdravih prostovoljcih.
Oral use.
Način uporabe peroralno
• low/high blood pressure, widening of blood vessels
• hitrejše bitje srca • nizek/visok krvni tlak, razširitev
Mycophenolate mofetil Teva 500 mg film-coated tablets
Mofetilmikofenolat Teva 500 mg filmsko obložene tablete
The capsule body is caramel opaque, printed with ‘250' axially in black ink.
Telo kapsule je karamelne barve s črnim napisom “250”v smeri osi kapsule Glava kapsule je svetlo modra s črnim napisom “M” v smeri osi kapsule.
Mycophenolate mofetil Teva 250 mg hard capsules
Mofetilmikofenolat Teva 250 mg trde kapsule
Red iron oxide (E172)
Telo rdeči železov oksid (E172)
• chest cold, sore throat, inflammation of the sinuses, stuffy and runny nose, sneezing
• okužba zgornjih dihal, vnetje grla, vnetje sinusov, zamašen nos in izcedek iz nosu kihanje.
Because of the potential for serious adverse reactions to mycophenolate mofetil in breast-fed infants, Mycophenolate mofetil Teva is contraindicated in breast-feeding mothers (see section 4.3).
Zaradi možnih resnih škodljivih vplivov mofetilmikofenolata na dojenčke je zdravilo Mofetilmikofenolat Teva pri doječih materah kontraindicirano
Precautions to be taken before handling or administering the medicinal product Because mycophenolate mofetil has demonstrated teratogenic effects in rats and rabbits, Mycophenolate mofetil Teva capsules should not be opened or crushed to avoid inhalation or direct contact with skin or mucous membranes of the powder contained in Mycophenolate mofetil Teva capsules.
Mofetilmikofenolat Teva ne smemo odpreti ali drobiti, da se izognemo vdihavanju ali neposrednemu stiku praška v kapsulah zdravila Mycophenolate mofetil Teva s kožo ali sluznico.
Pharmacokinetic parameters were evaluated in 49 paediatric renal transplant patients (aged 2 to 18°years) given 600°mg/m2 mycophenolate mofetil orally twice daily.
Pediatrična populacija Farmakokinetične parametre so opazovali pri 49 otrocih in mladostnikih z ledvičnim presadkom (starih od 2 do
The nonclinical toxicity profile of mycophenolate mofetil appears to be consistent with adverse events observed in human clinical trials which now provide safety data of more relevance to the patient population (see section 4.8).
Neklinični profil toksičnosti mofetilmikofenolata je v skladu z neželenimi učinki, ki so jih opazili pri kliničnih študijah pri ljudeh,
Pneumonia, influenza, respiratory tract infection, respiratory moniliasis, gastrointestinal infection, candidiasis, gastroenteritis, infection, bronchitis,
Infekcijske in parazitske bolezni zelo pogosti sepsa, gastrointestinalna kandidoza, okužba urinarnega trakta, herpes simpleks, herpes zoster pogosti pljučnica, gripa, okužba respiratornega trakta, respiratorna moniliaza, gastrointestinalna okužba, kandidoza, gastroenteritis,
Trimethoprim/sulfamethoxazole No effect on the bioavailability of MPA was observed.
Vplivov na biološko uporabnost mikofenolne kisline niso opazili.
Mycophenolate mofetil Teva 250mg hard capsules Mycophenolate mofetil
Navodilo za uporabo Mofetilmikofenolat Teva 250 mg trde kapsule mofetilmikofenolat
What Mycophenolate mofetil Teva looks like and contents of the pack
Izgled zdravila Mofetilmikofenolat Teva in vsebina pakiranja trde kapsule
Mycophenolate mofetil Teva 500 mg film-coated tablets Mycophenolate mofetil
Mofetilmikofenolat Teva 500 mg filmsko obložene tablete mofetilmikofenolat
Mycophenolic acid (MPA) is the active metabolite of mycophenolate mofetil. Renal transplant rejection does not lead to changes in MPA pharmacokinetics; dosage reduction or interruption of Mycophenolate mofetil Teva is not required.
Zavrnitev ledvičnega presadka ne spremeni farmakokinetike mikofenolne kisline, zmanjšanje odmerkov ali prekinitev zdravljenja z zdravilom
• if you are planning to become pregnant, or if you get pregnant while taking Mycophenolate mofetil
- če nameravate zanositi ali zanosite med jemanjem zdravila Mofetilmikofenolat Teva.
Talk to your doctor or pharmacist before taking Mycophenolate mofetil Teva.
Vendar pa do obiska zdravnika nadaljujte z jemanjem zdravila Mofetilmikofenolat Teva.
Renal impairment
• vnetje prebavil
Therefore, a change in the dose of Mycophenolate mofetil Teva should not normally be necessary in the absence of clinical evidence of graft dysfunction.
Zato v odsotnosti kliničnih znakov slabega delovanja presadka odmerka zdravila Mofetilmikofenolat Teva ponavadi ni potrebno spreminjati.
Pancytopenia, leukocytosis
(diareja, levkopenija).
Men must not donate semen during treatment with Mycophenolate mofetil Teva and for at least 90°days after stopping treatment.
Bolniki med zdravljenjem in vsaj še 90 dni po končanem zdravljenju z zdravilom Mofetilmikofenolat Teva ne smete darovati sperme.
Each capsule contains 250 mg mycophenolate mofetil. For the full list of excipients, see section 6.1.
Ena kapsula vsebuje 250 mg mofetilmikofenolata - Druge sestavine zdravila so:
Indigo carmine aluminium lake (E132) Iron oxide black (E172)
Pokrovček indigotin (E132) titanov dioksid (E171) želatina
If you take more Mycophenolate mofetil Teva than you should
Če ste vzeli večji odmerek zdravila Mofetilmikofenolat Teva, kot bi smeli Pomembno je, da ne vzamete preveč tablet.
The need for contraception prior to, during and after treatment with mycophenolate mofetil, including details of the duration of time for which contraception must be continued after cessation of therapy, will be clearly stated.
vključno s podrobnostmi o času, ko je treba kontracepcijo uporabljati še po zaključku zdravljenja.
Hypromellose (HPMC 2910) Titanium dioxide (E171)
indigotin (E132) titanov dioksid (E171) želatina
Patients with a body surface area greater than 1.5 m2 may be prescribed Mycophenolate mofetil Teva capsules at a dose of 1 g twice daily (2 g daily dose).
predpišemo kapsule zdravila Mofetilmikofenolat Teva v odmerku 1 g dvakrat na dan (dnevni odmerek 2 g).
• Renal abnormalities.
• ledvične nenormalnosti.
≥1/100 to <1/10 of patients treated with mycophenolate mofetil in the controlled clinical trials of renal
≥1/100 do <1/10 bolnikov, zdravljenih z mofetilmikofenolatom v nadziranih kliničnih preskušanjih bolnikov z ledvičnim (podatki za 2 g), srčnim ali jetrnim presadkom, so našteti v spodnji preglednici.
You must not donate blood during treatment with Mycophenolate mofetil Teva and for at least 6°weeks after stopping treatment.
Bolnice in bolniki med zdravljenjem z mofetilmikofenolatom in vsaj še 6 tednov po njegovi ukinitvi ne smejo darovati krvi.
Each dose must be taken with food.
Vsak odmerek zdravila je treba zaužiti skupaj s hrano.
For adults, the recommended dose is 300 mg once a day.
Pri odraslih je priporočeni odmerek 300 mg enkrat na dan.
Further information on Atazanavir Krka can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/atazanavir-krka.
Nadaljnje informacije o zdravilu Atazanavir Krka so na voljo na spletni strani agencije: ema.europa.eu/medicines/human/EPAR/atazanavir-krka.
Atazanavir Krka is available as capsules (150 mg, 200 mg and 300 mg).
Zdravilo Atazanavir Krka je na voljo v obliki kapsul (150 mg, 200 mg in 300 mg).
It blocks an enzyme called protease, which is needed for the HIV virus to multiply.
Zavira encim, imenovan proteaza, ki je potreben za razmnoževanje virusa HIV.
It can only be obtained with a prescription and treatment should be started by a doctor who has experience in the treatment of HIV infection.
Predpisovanje in izdaja zdravila je le na recept, zdravljenje z njim pa mora uvesti zdravnik, ki ima izkušnje z zdravljenjem okužbe z virusom HIV.
Studies on the benefits and risks of the active substance in the authorised use have already been carried out with the reference medicine, Reyataz, and do not need to be repeated for Atazanavir Krka.
Študije o koristih in tveganjih učinkovine pri odobrenem načinu uporabe so že bile izvedene z referenčnim zdravilom Reyataz, zato jih ni treba ponoviti za zdravilo Atazanavir Krka.
What measures are being taken to ensure the safe and effective use of Atazanavir Krka?
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Atazanavir Krka?
The medicine is not expected to work in patients in whom many medicines in the same class as Atazanavir Krka (protease inhibitors) do not work.
Ni pričakovati, da bi zdravilo učinkovalo pri bolnikih, pri katerih številna zdravila istega razreda kot zdravilo Atazanavir Krka (zaviralci proteaze) ne učinkujejo.
It is used together with low-dose ritonavir and other antiviral medicines to treat patients aged 6 years and over.
Uporablja se skupaj z majhnim odmerkom ritonavirja in drugimi protivirusnimi zdravili za zdravljenje bolnikov, starejših od šest let.
Because Atazanavir Krka is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Ker je zdravilo Atazanavir Krka generično zdravilo in je bioekvivalentno referenčnemu zdravilu, so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
Blocking the enzyme prevents the virus from multiplying, slowing down the spread of infection.
Zaviranje encima prepreči razmnoževanje virusa, kar upočasni širjenje okužbe.
Atazanavir Krka is an HIV medicine used to treat patients infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immunodeficiency syndrome (AIDS).
Zdravilo Atazanavir Krka je zdravilo proti virusu HIV, ki se uporablja za zdravljenje bolnikov, okuženih z virusom humane imunske pomanjkljivosti tipa 1 (HIV-1), tj. virusom, ki povzroča sindrom pridobljene imunske pomanjkljivosti (aids).
Doctors should prescribe Atazanavir Krka only after they have looked at which medicines the patient has taken and carried out tests to establish that the virus is likely to respond to Atazanavir Krka.
Zdravniki lahko zdravilo Atazanavir Krka predpišejo šele, ko preverijo, katera zdravila je bolnik jemal prej, in ko opravijo preiskave za ugotovitev verjetnosti, da se bo virus odzval na zdravilo Atazanavir Krka.
Atazanavir Krka, taken in combination with other antiviral medicines, reduces the amount of HIV in the blood and keeps it at a low level.
Zdravilo Atazanavir Krka v kombinaciji z drugimi protivirusnimi zdravili zniža količino virusa HIV v krvi in jo vzdržuje na nizki ravni.
A small dose of another medicine, ritonavir, is normally given at the same time as a ‘booster'.
Hkrati se običajno daje majhen odmerek drugega zdravila, ritonavirja, kot „stopnjevalca“.
As for every medicine, the company provided studies on the quality of Atazanavir Krka.
Tako kot za vsako zdravilo je podjetje predložilo študije o kakovosti zdravila Atazanavir Krka.
Atazanavir Krka is normally given with ritonavir to boost its action but doctors can consider stopping ritonavir in adults in some specific situations.
Zdravilo Atazanavir Krka se običajno daje sočasno z ritonavirjem za okrepitev njegovega delovanja, zdravniki pa lahko v nekaterih posebnih primerih razmislijo o prenehanju dajanja ritonavirja pri odraslih.
The European Medicines Agency concluded that, in accordance with EU requirements, Atazanavir Krka has been shown to have comparable quality and to be bioequivalent to Reyataz.
Evropska agencija za zdravila je zaključila, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Atazanavir Krka primerljivo raven kakovosti kot referenčno zdravilo Reyataz ter da mu je bioekvivalentno.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Atazanavir Krka have been included in the summary of product characteristics and the package leaflet.
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Atazanavir Krka upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
Side effects reported with Atazanavir Krka are carefully evaluated and any necessary action taken to protect patients.
Neželeni učinki, o katerih so poročali pri zdravilu Atazanavir Krka, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
What are the benefits and risks of Atazanavir Krka?
Kakšne so koristi in tveganja zdravila Atazanavir Krka?
For more information about using Atazanavir Krka, see the package leaflet or contact your doctor or pharmacist.
Za več informacij glede uporabe zdravila Atazanavir Krka glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
An overview of Atazanavir Krka and why it is authorised in the EU
Pregled zdravila Atazanavir Krka in zakaj je odobreno v EU
In younger patients, the dose of Atazanavir Krka depends on body weight.
Pri mlajših bolnikih je odmerek zdravila Atazanavir Krka odvisen od njihove telesne mase.
This allows a lower dose of atazanavir to be used for the same antiviral effect.
Tako za dosego enakega protivirusnega učinka zadošča manjši odmerek atazanavirja.
Why is Atazanavir Krka authorised in the EU?
Zakaj je bilo zdravilo Atazanavir Krka odobreno v EU?
As for all medicines, data on the use of Atazanavir Krka are continuously monitored.
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Atazanavir Krka stalno spremljajo.
This means that Atazanavir Krka contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the EU called Reyataz.
To pomeni, da vsebuje enako učinkovino in deluje na enak način kot „referenčno zdravilo“, ki je že odobreno v EU in se imenuje Reyataz.
Atazanavir Krka contains the active substance atazanavir and is a ‘generic medicine'.
Zdravilo Atazanavir Krka vsebuje učinkovino atazanavir in je „generično zdravilo“.
Ritonavir slows down the break-down of atazanavir, increasing the levels of atazanavir in the blood.
Ta upočasnjuje hitrost razgradnje atazanavirja in s tem povečuje njegove ravni v krvi.
Other information about Atazanavir Krka
Druge informacije o zdravilu Atazanavir Krka
The active substance in Atazanavir Krka, atazanavir, is a protease inhibitor.
Učinkovina zdravila Atazanavir Krka, atazanavir, je zaviralec proteaze.
What is Atazanavir Krka and what is it used for?
Kaj je zdravilo Atazanavir Krka in za kaj se uporablja?
Atazanavir Krka does not cure HIV infection or AIDS but, when used in combination with other antivirals, it holds off the damage to the immune system and the development of infections and diseases associated with AIDS.
Ne ozdravi okužbe z virusom HIV ali aidsa, lahko pa v kombinaciji z drugimi protivirusnimi zdravili upočasni slabšanje imunskega sistema ter prepreči razvoj okužb in bolezni, povezanih z aidsom.
Therefore, the Agency's view was that, as for Reyataz, the benefit of Atazanavir Krka outweighs the identified risk and it can be authorised for use in the EU.
Zato je menila, da koristi zdravila Atazanavir Krka, enako kot pri zdravilu Reyataz, odtehtajo znana tveganja, in se lahko zdravilo odobri v EU.
How has Atazanavir Krka been studied?
Kako je bilo zdravilo Atazanavir Krka raziskano?
How is Atazanavir Krka used?
Kako se zdravilo Atazanavir Krka uporablja?
How does Atazanavir Krka work?
Kako zdravilo Atazanavir Krka deluje?
The medicine should be taken around the same time every day and the need for the oncea-day dosing should be assessed regularly.
Zdravilo je treba jemati vsak dan ob približno istem času, pri čemer je treba potrebo po odmerjanju enkrat dnevno redno ocenjevati.